Nature and Importance of the Biostatistics and Data Management Core. The Biostatistics and Data Management Core for the M.D. Anderson Genitourinary Cancer SPORE will serve multiple needs for the planning and conduct of the SPORE's translational research. This resource will be used for hypothesis refinement, experimental design, data management, quality control, resu7lt analysis and informative presentation of refinement, experimental design, data management, quality control, result analysis and informative presentation of results, and will function across all projects of the SPORE. From a biostatistical perspective, design and analysis of laboratory and clinical projects will be performed in collaboration with Dr. Yu Shen, Dr.. Dennis Johnston, Dr. Dorota Doherty and Mr. Mark Munsell. From a clinical and informatics perspective, Core services will be provided in collaboration with Dr. Randall Millikan. Data from SPORE clinical trials and laboratory projects will be entered into a custom database application recently launched within the Center for GU Oncology. Among other advantages, this computerized database will facilitate continuous monitoring of clinical trial results and will allow for automated data audits. This, from inception to reporting, translational experiments will benefit from SPORE resource that will be used to augment existing M.D. Anderson biostatistics resources and to align these considerable resources with SPORE research objectives.
The specific aims of the Biostatistics and Data Management Core are: 1. To provide guidance in the design and conduct of clinical trials and other experiments arising from the ongoing research of the SPORE. 2. To provide the innovative statistical modeling, simulation techniques, and data analyses needed by the Projects, Developmental Projects, and other Cores to achieve their Specific Aims. 3. To ensure that the results of all projects are based on well-designed experiments and are appropriately interpreted.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA091846-01
Application #
6543315
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2001-09-25
Project End
2006-08-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Duplisea, Jonathan J; Mokkapati, Sharada; Plote, Devin et al. (2018) The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. World J Urol :
Choi, Woonyoung; McConkey, David (2018) Reply to Joshua A. Linscott, Angela B. Smith, and Jesse D. Sammon's Letter to the Editor re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas D Eur Urol 73:e104-e105
Zhang, Miao; Adeniran, Adebowale J; Vikram, Raghunandan et al. (2018) Carcinoma of the urethra. Hum Pathol 72:35-44
Wang, Gang; Xiao, Li; Zhang, Miao et al. (2018) Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Hum Pathol 79:57-65
Zhang, Shizhen; Wang, Yan; Bondaruk, Jolanta et al. (2018) Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test. Eur Urol Focus :
Jazzar, Usama; Yong, Shan; Klaassen, Zachary et al. (2018) Impact of psychiatric illness on decreased survival in elderly patients with bladder cancer in the United States. Cancer 124:3127-3135
Westhoff, Ellen; Wu, Xifeng; Kiemeney, Lambertus A et al. (2018) Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer. Int J Cancer 142:1797-1804
Roth, Beat; Jayaratna, Isuru; Sundi, Debasish et al. (2017) Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis. Oncotarget 8:34205-34222
Shore, Neal D; Boorjian, Stephen A; Canter, Daniel J et al. (2017) Intravesical rAd-IFN?/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol 35:3410-3416
Lin, Moubin; Zhang, Liren; Hildebrandt, Michelle A T et al. (2017) Common, germline genetic variations in the novel tumor suppressor BAP1 and risk of developing different types of cancer. Oncotarget 8:74936-74946

Showing the most recent 10 out of 247 publications